Risankizumab (SKYRIZI, AbbVie), outperformed secukinumab (Cosentyx, Novartis) in a head-to-head phase 3 study comparing the two treatments in adult patients with moderate to severe plaque psoriasis, according to data released by the company Jan. 14.
Newly published results from a phase 3 study demonstrate the superiority of bimekizumab over adalimumab for plaque psoriasis.
Psoriasis often has a greater impact on quality of life in patients with skin of color as the condition and its treatment can result in long-lasting pigmentary changes.
The 2019 joint American Academy of Dermatology and National Psoriasis Foundation phototherapy treatment of psoriasis guidelines comprehensively updates dermatologists and other providers on the state-of-the art use of various light modalities to treat psoriasis patients.
Oral health, habits and diet may influence disease severity in psoriasis, says a study published in the Dermatology Online Journal.
A recent study examined whether gluten intake in adulthood increases the risk of developing psoriasis, psoriatic arthritis, and atopic dermatitis.
Weight-based dosing of apremilast appeared to ensure comparable efficacy, safety and tolerability with in kids as in adults, and should be explored in future studies.
Study shows measurement of early ustekinumab levels could be used to direct treatment strategy in psoriasis.
Researchers in Taiwan investigated whether behavioral modifications such as weight reduction, alcohol abstinence, smoking cessation and exercise could impact psoriasis severity. Read what they discovered in this article.
Discover key takeaways from the American Academy of Dermatology and National Psoriasis Foundation joint guidelines for the management and treatment of psoriasis with phototherapy published in the September issue of the Journal of American Academy of Dermatology.